Abstract

The invention relates to an iminosugar prodrug compound of General Formula (I) or General Formula (II): Compounds and compositions comprising the same exhibit low toxicity and are efficacious against Lysosomal Storage Disorders (LSDs), neurodegenerative disorders and Down Syndrome. Further, by masking the iminosugar API, well documented adverse effects associated with iminosugar APIs, including diarrhoea and other gut-related issues can be minimized or even eliminated. The invention also relates to methods of treating LSDs, neurodegenerative disorders or Down Syndrome using the compounds of General Formula (I) or General Formula (II).

IPC Classes  ?

• C07F 9/59 - Hydrogenated pyridine rings
• C07F 9/26 - Amides of acids of phosphorus containing P-halide groups
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention concerns a modified adenoviral vector of serotype Ad5 comprising cancer selective targeting motif; a pharmaceutical composition comprising same; a combination therapeutic comprising same, the use of said adenoviral vector or pharmaceutical composition or combination therapeutic as a medicament and, in particular to treat cancer; and a method of treating cancer using said modified adenoviral vector or pharmaceutical composition or combination therapeutic.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• C07K 14/075 - Adenoviridae
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present disclosure relates inter alia to a new T-cell receptor (TCR), an immune cell, particularly a T-cell expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, and a method of treating cancer using said TCR, said cell, said vector, said pharmaceutical composition or bispecific comprising said TCR.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

The present invention provides compounds of Formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABAA receptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α5-GABAA receptors, including depression and cognitive impairment, for example, cognitive impairment associated with a psychotic disorder such as schizophrenia. The present invention provides compounds of Formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABAA receptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α5-GABAA receptors, including depression and cognitive impairment, for example, cognitive impairment associated with a psychotic disorder such as schizophrenia.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems
• C07D 493/04 - Ortho-condensed systems
• C07D 493/08 - Bridged systems
• C07D 493/10 - Spiro-condensed systems
• C07D 498/04 - Ortho-condensed systems

Abstract

23222O- functional group.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07D 207/327 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 333/78 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The invention relates to a novel phosphoantigen (PAg) prodrug compound which provides for a potent activation of therapeutically active γδ T cells. The PAg prodrug compound of the in- vention can be used for the preparation of therapeutically active γδ T cells as well as in the immunotherapy of different diseases, and in particular different types of cancer. The invention further relates to a method for expanding γδ T-cells ex vivo which makes use of the PAg pro-drug compound of the invention. Also provided are γδ T-cells which have been expanded with the PAg prodrug compound of the invention and pharmaceutical compositions comprising such expanded cells and/or the PAg prodrug compound of the invention.

IPC Classes  ?

• A61P 19/00 - Drugs for skeletal disorders
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07F 9/44 - Amides thereof

Abstract

A sample sensor (100) has a AIGaN/GaN high electron mobility transistor (HEMT) (102) comprising a semiconductor portion comprising an AIGaN/GaN heterojunction, a source (108) a drain (114) and a gate comprising a gate foot (140) with a functionalised gate head detection surface thereon, the gate head being offset from the source and drain, and the gate head with the patterned detection surface spans over the entire device area, wherein the detection surface has a capture reagent provided thereon, wherein the capture reagent binds or otherwise associates with a target antigen or analyte.

IPC Classes  ?

• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS

Abstract

The invention relates to a method for determining the number and nature of DNA double-strand breaks (DSBs) in a nucleic acid sample, ideally gDNA; a kit of parts for performing the aforesaid method including at least a plurality of oligonucleotides for ligating to said nucleic acid sample and providing at least a first hybridization site (RD1 SP or RD2 SP) to which at least one read sequencing primer can hybridise; and oligonucleotides for use in said kit and said method.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

Abstract

The invention relates to a compound of General Formula (I): (General Formula I) wherein R1and R2 are as defined herein; for use in the treatment of neurodegenerative diseases or conditions that are characterised by an elevated level of Ubiquitin Ser65 phosphorylation and/or in the treatment of cancer. The invention also relates to pharmaceutical compositions and combination therapeutic agents comprising compounds of formula (I) for treating these conditions as well to a method of treating such diseases and conditions using the compounds of General Formula (I).

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 35/00 - Antineoplastic agents

Abstract

The invention concerns a modified low seroprevalence adenovirus: a pharmaceutical composition comprising same; and a method of treating cancer using same.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• A61P 35/00 - Antineoplastic agents
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention concerns a modified adenoviral vector of serotype Ad5 comprising a suicide transgene; a pharmaceutical composition comprising same; a combination therapeutic comprising same, the use of said adenoviral vector or pharmaceutical composition or combination therapeutic as a medicament and, in particular to treat cancer; and a method of treating a disease, such as cancer, using said modified adenoviral vector or pharmaceutical composition or combination therapeutic.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• C07K 14/075 - Adenoviridae
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

A filter element for filtering a fluid is described. The filter element comprises diamond particles fixed to a filter substrate. Also described is a method for the manufacture of the filter element and a filtration device comprising the filter element.

IPC Classes  ?

• B01D 39/20 - Other self-supporting filtering material of inorganic material, e.g. asbestos paper or metallic filtering material of non-woven wires
• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres

Abstract

System comprising a gas turbine engine fuel injection apparatus (11) arranged to deliver to a combustion chamber (9) of a gas turbine engine a first injection fluid comprising a first fuel and a second injection fluid comprising a second fuel. The apparatus is arranged to deliver the first and second injection fluids in a manner such that the first injection fluid is delivered in a first stream and the second injection fluid is delivered in a second stream. Further, such that there is a delivery zone (47) corresponding to a first location at which both the first and second streams have been delivered in which the first stream is substantially radially surrounded by the second stream.

IPC Classes  ?

• F23R 3/36 - Supply of different fuels
• F23R 3/34 - Feeding into different combustion zones
• F23R 3/16 - Continuous combustion chambers using liquid or gaseous fuel characterised by the air-flow or gas-flow configuration with devices inside the flame tube or the combustion chamber to influence the air or gas flow
• F23R 3/00 - Continuous combustion chambers using liquid or gaseous fuel

Abstract

There is provided inter alia an isolated anti-cancer T-cell receptor (TCR), or anti- cancer binding fragment thereof, that binds to a plurality of cancer polypeptide antigens or antigenic peptide fragments thereof wherein said cancer polypeptide antigens or antigenic peptide fragments thereof are distinct from each other and are presented at the cell surface of one or more than one type of cancer cell.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors

Abstract

The invention relates to a method for determining the number and nature of DNA double-strand breaks (DSBs) in a nucleic acid sample, ideally gDNA; a kit of parts for performing the aforesaid method including at least a plurality of oligonucleotides for ligating to said nucleic acid sample and providing at least a first hybridization site (RD1 SP or RD2 SP) to which at least one read sequencing primer can hybridise; and oligonucleotides for use in said kit and said method.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to bifunctional compounds (PROTACs) of formula (I) that target the degradation of KAT2A and KAT2B, their manufacture, pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds of the invention are useful in the treatment of diseases and medical conditions associated with KAT2A and KAT2B, including, for example, cancer, autoimmune conditions, and inflammatory conditions.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no increase is observed in the one or more biomarker for SIRS, in the sample obtained from the patient relative to the corresponding reference value; and There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no increase is observed in the one or more biomarker for SIRS, in the sample obtained from the patient relative to the corresponding reference value; and wherein the patient is diagnosed as having SIRS, when an increase is observed in the one or more biomarker for SIRS, and no increase is observed in the one or more biomarker for sepsis, in the sample obtained from the patient relative to the corresponding reference value.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

ParaburkholderiaParaburkholderia cells comprising a heterologous biosynthetic gene cluster for producing an antimicrobial compound, compositions thereof, and their uses in methods of preventing, reducing or treating infection of a plant with a plant pathogen, and/or in improving plant growth.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 7/42 - Hydroxy carboxylic acids
• C12P 17/04 - Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin
• C12P 17/10 - Nitrogen as only ring hetero atom

Abstract

A method of controlling an electricity distribution network, wherein the electricity distribution network is a mesh network including a plurality of loads and there is a voltage-source converter connected to a point in the network. The method comprises, while using the voltage-source converter to try to hold the voltage magnitude constant at said point, establishing a record of how, at said point, the real power flowing between the network and the voltage-source converter varies with variation of the reactive power that the voltage-source converter causes to flow between itself and the network, using a reactive-power value, proportional to the sum of the reactive-power draws of the loads, in order to look up a real-power value from the record, and configuring the voltage-source converter to supply into the network at said point reactive and real power at said reactive- and real-power values, respectively.

IPC Classes  ?

• H02J 3/16 - Circuit arrangements for ac mains or ac distribution networks for adjusting voltage in ac networks by changing a characteristic of the network load by adjustment of reactive power
• H02J 3/46 - Controlling the sharing of output between the generators, converters, or transformers

Abstract

A method of producing a coated electrical steel is described. The method comprises: providing an electrical steel substrate; providing a coating composition, said coating composition comprising silica particles, metal phosphate, and a graphitic oxide; applying the coating composition to at least a portion of the electrical steel substrate; and subjecting the coating composition to at least one curing treatment to form a tension coating layer.

IPC Classes  ?

• C21D 8/02 - Modifying the physical properties by deformation combined with, or followed by, heat treatment during manufacturing of plates or strips
• C01B 32/198 - Graphene oxide
• C21D 8/12 - Modifying the physical properties by deformation combined with, or followed by, heat treatment during manufacturing of articles with special electromagnetic properties
• C23C 22/74 - Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals characterised by the process for obtaining burned-in conversion coatings
• H01F 1/18 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials metals or alloys in the form of sheets with insulating coating

Abstract

The present invention concerns a snow stake for measuring snow depth. This invention also concerns a method of manufacturing a snow stake for measuring snow depth. The snow stake comprises an elongate body and a strip of dual-purpose emitters/detectors mechanically attached to the elongate body. Each dual-purpose emitter/detector is configured to be able to both emit light and detect light. A control unit controls the dual-purpose emitters/detectors to emit light, or detect light and switch the function of the dual-purpose emitters/detectors over the course of a measurement process. Each of the dual-purpose emitters/detectors is an LED.

IPC Classes  ?

• G01B 11/22 - Measuring arrangements characterised by the use of optical techniques for measuring depth
• G01F 23/292 - Light
• G01W 1/14 - Rainfall or precipitation gauges

Abstract

The present invention relates to a product containing Miglustat alone, or to a combination product containing parenteral Trehalose and oral Miglustat, for treating lysosomal diseases such as the CLN3 disease.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention is concerned with a method and an instrument for measuring visual field sensitivity wherein the method relies on measuring, across a subject's visual field, the subject's response to a fixed-luminance stimulus, the area of which is modulated on subsequent stimulation; and said instrument is adapted to emit, at one or more locations across a subject's visual field, a fixed-luminance stimulus whose area is modulated on subsequent stimulation and wherein the instrument is also adapted to record the subject's response to said fixed-luminance stimulus by comparing the subject's response with the response in an age-matched normal group or by comparing the response to a prior determined baseline in order to identify any change in visual field sensitivity.

IPC Classes  ?

• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types

Abstract

The invention concerns a device for introducing microneedles into the skin of a subject; and a method for inserting microneedles into the skin of a subject comprising use of said device.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

The invention concerns a device for use in ligament surgery to locate the best graft attachment site, including parts thereof; a kit of parts for use in ligament surgery; and a method for performing ligament surgery.

IPC Classes  ?

• A61F 2/08 - MusclesTendonsLigaments
• A61B 17/06 - NeedlesHolders or packages for needles or suture materials
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The present disclosure relates inter alia to a new T-cell receptor (TCR), an immune cell, particularly a T-cell expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, and a method of treating cancer using said TCR, said cell, said vector, said pharmaceutical composition or bispecific comprising said TCR.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Inhibitors of MAPK3 (ERK1 MAP kinase), in particular to polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents, are disclosed. Related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway, are also disclosed. Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.

IPC Classes  ?

• A61K 38/55 - Protease inhibitors
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a self-hybridising primer for use in a nucleic acid detection assay, typically involving amplification of the target nucleic acid; a method for detecting nucleic acid in a sample using said primer and a kit of parts for performing the aforesaid method including at least one and ideally a plurality of said primers.

IPC Classes  ?

• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates

Abstract

The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia. The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

An antibody or antibody fragment that binds to complement protein C7 in isolation or as part of a protein complex and the various uses, for example for the treatment of a disease associated with the dysregulation of complement in a subject.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for ?5-subunit-containing GABAA receptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with ?5-GABAA receptors, including depression and cognitive impairment, for example, congintive impairment associated with a psychotic disorder such as schizophrenia.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• C07D 491/08 - Bridged systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems

Abstract

The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3AAA receptors, including depression and cognitive impairment, for example, congintive impairment associated with a psychotic disorder such as schizophrenia.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• C07D 491/08 - Bridged systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

The invention concerns a modified low seroprevalence adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.

IPC Classes  ?

• A61K 35/761 - Adenovirus

Abstract

The invention concerns a modified low seroprevalence adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• C12N 15/86 - Viral vectors
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A method of non-destructive testing using Lamb waves. The method is suitable for obtaining an indication of the thickness of a structure, such as a structure comprising a composite material. The method comprises the following steps: subjecting a structure (106) to excitation so as to generate Lamb waves within a region of interest (104) within the structure, wherein the excitation is multi-frequency excitation and generates a steady-state response within the region of interest; obtaining a set of spatial domain wavefield data which defines a velocity response of a surface of the structure at a plurality of sample locations within the region of interest; transforming the spatial domain wavefield data to the frequency domain to obtain a set of frequency domain wavefield data; using the set of frequency domain wavefield data to determine a frequency-wavenumber relationship for antisymmetric mode Lamb waves generated in the region of interest; calculating a plurality of mode filters using the frequency-wavenumber relationship so determined; and using each of the mode filters so calculated to obtain an indication of the thickness of the structure at the sample points. There is also provided a non-destructive testing apparatus (100).

IPC Classes  ?

• G01N 29/04 - Analysing solids
• G01N 29/265 - Arrangements for orientation or scanning by moving the sensor relative to a stationary material
• G01N 29/44 - Processing the detected response signal
• G01N 29/46 - Processing the detected response signal by spectral analysis, e.g. Fourier analysis

Abstract

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R1 and R2 are each independently selected from an optionally substituted C1-C8 alkyl, C1-C8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, —CN, —NO2, —NR3R4, —NR5(CO)R6; C1-C4 alkyl, C1-C4 alkoxy, —(CO)WR12, hydroxy, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F groups. The compounds may be effective in treating patients/animals infected with parasites selected from Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, Fasciola or Plasmodium parasites. Additionally or alternatively, the compounds of formula (I) may be effective in treating patients infected with pathogenic bacteria selected from S. aureus, MRSA and Enterococcus faecalis.

IPC Classes  ?

• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 339/08 - Six-membered rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents
• A61P 33/06 - Antimalarials
• A61P 33/12 - Schistosomicides

Abstract

The present disclosure provides a medical device (100) for inducing cell death in cancer cells. The device comprises a signal generator (102) arranged to generate a pulsed electrical signal, and a transmitter (116) arranged to receive the pulsed electrical signal and generate, in response to the electrical signal, an electric field in a treatment volume. The device (100) is arranged such that the pulsed electrical signal received by the transmitter (116) has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz. The present disclosure also provides a method of inducing cell death. The method comprising a step of generating, using a transmitter (116), a pulsed time varying electric field in a treatment volume comprising a volume of cells to be treated. The electric field has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz.

IPC Classes  ?

• A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling

Abstract

The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses

Abstract

The invention concerns a novel acoustofluidic device to separate acoustically active particles from fluids comprising a novel device arrangement for improved acoustic pressure and particle velocity; and a method of separating particles from a fluid comprising use of same.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01D 21/28 - Mechanical auxiliary equipment for acceleration of sedimentation, e.g. by vibrators or the like
• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction

Abstract

System comprising a gas turbine engine fuel injection apparatus (11) arranged to deliver to a combustion chamber (9) of a gas turbine engine a first injection fluid comprising a first fuel and a second injection fluid comprising a second fuel. The apparatus is arranged to deliver the first and second injection fluids in a manner such that the first injection fluid is delivered in a first stream and the second injection fluid is delivered in a second stream. Further, such that there is a delivery zone (47) corresponding to a first location at which both the first and second streams have been delivered in which the first stream is substantially radially surrounded by the second stream.

IPC Classes  ?

• F23R 3/34 - Feeding into different combustion zones
• F02C 7/224 - Heating fuel before feeding to the burner
• F23R 3/36 - Supply of different fuels

Abstract

The present invention concerns a snow stake for measuring snow depth. This invention also concerns a method of manufacturing a snow stake for measuring snow depth. The snow stake comprises an elongate body and a strip of dual-purpose emitters/detectors mechanically attached to the elongate body. Each dual-purpose emitter/detector is configured to be able to both emit light and detect light. A control unit controls the dual-purpose emitters/detectors to emit light, or detect light and switch the function of the dual-purpose emitters/detectors over the course of a measurement process. Each of the dual-purpose emitters/detectors is an LED.

IPC Classes  ?

• G01W 1/14 - Rainfall or precipitation gauges
• G01F 23/292 - Light

Abstract

The present invention concerns a snow stake for measuring snow depth. This invention also concerns a method of manufacturing a snow stake for measuring snow depth. The snow stake comprises an elongate body and a strip of dual-purpose emitters/detectors mechanically attached to the elongate body. Each dual-purpose emitter/detector is configured to be able to both emit light and detect light. A control unit controls the dual-purpose emitters/detectors to emit light, or detect light and switch the function of the dual-purpose emitters/detectors over the course of a measurement process. Each of the dual-purpose emitters/detectors is an LED.

IPC Classes  ?

• G01F 23/292 - Light
• G01W 1/14 - Rainfall or precipitation gauges

Abstract

The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof, wherein X1, L1, R1, R2, R3, R4AAA receptors, including, for example anxiety disorders.

IPC Classes  ?

• A61P 25/20 - HypnoticsSedatives
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61P 25/22 - Anxiolytics
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof, wherein X1, L1, R1, R2, R3, R4, Ring A, n and p are as described herein. The compounds of the present invention have affinity for ?2- and/or ?3-subunit-5 containing GABAA receptors. The present invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with ?2- and/or ?3-GABAA receptors, including, for example anxiety disorders.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 25/00 - Drugs for disorders of the nervous system
• C07D 215/54 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07D 471/10 - Spiro-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

The invention relates to a method for determining the number and nature of DNA double-strand breaks (DSBs) in a nucleic acid sample, ideally gDNA; a kit of parts for performing the aforesaid method including at least a plurality of oligonucleotides for ligating to said nucleic acid sample and providing at least a first hybridization site (RD1 SP or RD2 SP) to which at least one read sequencing primer can hybridise; and oligonucleotides for use in said kit and said method.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The invention relates to a method for determining the number and nature of DNA double-strand breaks (DSBs) in a nucleic acid sample, ideally gDNA; a kit of parts for performing the aforesaid method including at least a plurality of oligonucleotides for ligating to said nucleic acid sample and providing at least a first hybridization site (RD1 SP or RD2 SP) to which at least one read sequencing primer can hybridise; and oligonucleotides for use in said kit and said method.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

The present invention relates to a product containing Miglustat alone, or to a combination product containing parenteral Trehalose and oral Miglustat, for treating lysosomal diseases such as the CLN3 disease.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a product containing Miglustat alone, or to a combination product containing parenteral Trehalose and oral Miglustat, for treating lysosomal diseases such as the CLN3 disease.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a compound of general formula (I): The invention relates to a compound of general formula (I): The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl3 and are useful for the treatment of cancer, particularly metastatic cancer.

IPC Classes  ?

• C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 213/40 - Acylated substituent nitrogen atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• C07C 237/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Abstract

A device (1) for introducing microneedles (4) into the skin of a subject; and a method for inserting microneedles into the skin of a subject comprising use of said device.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Compounds can be used as catalysts, particularly in ring-opening polymerization reactions, including ring-opening co-polymerization (ROCOP) reactions, or in isocyanate trimerization reactions. The compounds have the formula L-M-Xn, where L is a pyridyl-bis(iminophenolate) ligand, M is a metal ion, X is a co-ligand to balance the charge of the compound, and n is an integer from 0 to 7. The compounds can be prepared by base condensation of a pyridyl-diamine compound with an aldehyde or ketone.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C08G 63/08 - Lactones or lactides
• C08G 63/84 - Boron, aluminium, gallium, indium, thallium, rare earth metals, or compounds thereof
• C08G 63/82 - Preparation processes characterised by the catalyst used
• C08G 59/02 - Polycondensates containing more than one epoxy group per molecule
• C08G 59/12 - Polycondensates containing more than one epoxy group per molecule of polycarboxylic acids with epihalohydrins or precursors thereof
• C07F 5/06 - Aluminium compounds
• C07F 7/28 - Titanium compounds
• C07F 3/06 - Zinc compounds
• C07F 11/00 - Compounds containing elements of Groups 6 or 16 of the Periodic Table
• C07F 15/06 - Cobalt compounds

Abstract

A method of controlling an electricity distribution network, wherein the electricity distribution network is a mesh network including a plurality of loads and there is a voltage- source converter connected to a point in the network. The method comprises, while using the voltage-source converter to try to hold the voltage magnitude constant at said point, establishing a record of how, at said point, the real power flowing between the network and the voltage-source converter varies with variation of the reactive power that the voltage-source converter causes to flow between itself and the network, using a reactive- power value, proportional to the sum of the reactive-power draws of the loads, in order to look up a real-power value from the record, and configuring the voltage-source converter to supply into the network at said point reactive and real power at said reactive- and real- power values, respectively.

IPC Classes  ?

• H02J 3/48 - Controlling the sharing of the in-phase component
• H02J 3/50 - Controlling the sharing of the out-of-phase component

Abstract

An SOP for connection to a first feeder in an electricity distribution network, the SOP being configured to, when a feeder connected to the SOP is faulty, apply a diagnostic voltage to the feeder and make current and voltage measurements at the connection of the SOP to the feeder while the diagnostic voltage is being applied.

IPC Classes  ?

• G01R 31/42 - AC power supplies
• H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks
• H02J 3/36 - Arrangements for transfer of electric power between ac networks via a high-tension dc link
• H02M 1/32 - Means for protecting converters other than by automatic disconnection

Abstract

The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The invention relates to a compound of General Formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein. Compounds and compositions comprising the same exhibit high serum stability and potent activation of the γδ T-cell immune response, so are suitable for use in immunotherapy. The invention also relates to methods of immunotherapy using the compounds of General Formula (I). The invention relates to a compound of General Formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein. Compounds and compositions comprising the same exhibit high serum stability and potent activation of the γδ T-cell immune response, so are suitable for use in immunotherapy. The invention also relates to methods of immunotherapy using the compounds of General Formula (I).

IPC Classes  ?

• C07F 9/44 - Amides thereof
• A61P 37/04 - Immunostimulants
• A61P 35/00 - Antineoplastic agents
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A filter element for filtering a fluid is described. The filter element comprises diamond particles fixed to a filter substrate. Also described is a method for the manufacture of the filter element and a filtration device comprising the filter element.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/02 - Inorganic material
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 69/14 - Dynamic membranes
• B01D 71/04 - Glass

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

IPC Classes  ?

• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The invention concerns a device (1, 2, 3, 4) for use in ligament surgery to locate the best graft attachment site, including parts thereof; a kit of parts for use in ligament surgery; and a method for performing ligament surgery.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61F 2/08 - MusclesTendonsLigaments

Abstract

The invention concerns a modified oncolytic adenovirus of serotype Ad5; a pharmaceutical composition comprising same; and a method of treating cancer using same wherein said modified adenovirus comprises at least one point mutation(s) in the hexon hypervariable region 7 (HVR7 mutation) to prevent virus binding with coagulation factor 10 (FX); at least one point mutation(s) in the fiber knob region AB loop (KO1 mutation) to prevent virus binding with the coxsackie and adenovirus receptor (CAR); and at least one point mutation(s) in the penton integrin binding motif Arg-Gly-Asp (RGD) to prevent virus binding with αVβ3/αVβ5 integrin.

IPC Classes  ?

• A61K 35/761 - Adenovirus
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

An antibody or antibody fragment that binds to complement protein C7 in isolation or as part of a protein complex and the various uses, for example for the treatment of a disease associated with the dysregulation of complement in a subject.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

An antibody or antibody fragment that binds to complement protein C7 in isolation or as part of a protein complex and the various uses, for example for the treatment of a disease associated with the dysregulation of complement in a subject.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R1and R2181822, -NR3R4, -NR5(CO)R614144 alkoxy, -(CO)WR12322Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, FasciolaPlasmodiumS. aureusEnterococcus faecalis.Enterococcus faecalis.

IPC Classes  ?

• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents
• A61P 33/06 - Antimalarials
• A61P 33/12 - Schistosomicides
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Abstract

The invention relates to an anti-mitotic agent comprising at least one antibody, or an epitope thereof, that selectively binds the extracellular domain of at least one ZIP (Zrt, Irt-like Proteins) transporter protein to inhibit its function, specifically mitosis; a composition comprising same; and the use of said anti-mitotic agent or composition to treat a hyper proliferative disorder including cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The invention concerns a brace, ideally disposable, formed from a blank and, particularly but not exclusively, a neck or limb brace wherein the brace is contoured to fit about a wearer and comprises at least one, or a series of, crease line(s) that mirror(s) the contour of at least one edge of said brace and spaced from same by a selected amount whereby said edge can be folded or torn along at least one selected crease line to fit a wearer.

IPC Classes  ?

• A61F 5/058 - Splints
• A61F 5/055 - Cervical collars

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Inhibitors of MAPK3 (ERK1 MAP kinase), in particular polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents, are disclosed. Related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway, are also disclosed. Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The present disclosure provides a medical device (100) for inducing cell death in cancer cells. The device comprises a signal generator (102) arranged to generate a pulsed electrical signal, and a transmitter (116) arranged to receive the pulsed electrical signal and generate, in response to the electrical signal, an electric field in a treatment volume. The device (100) is arranged such that the pulsed electrical signal received by the transmitter (116) has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz. The present disclosure also provides a method of inducing cell death. The method comprising a step of generating, using a transmitter (116), a pulsed time varying electric field in a treatment volume comprising a volume of cells to be treated. The electric field has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz.

IPC Classes  ?

• A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/86 - Viral vectors
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention concerns a novel acoustofluidic device to separate acoustically active particles from fluids comprising a novel device arrangement for improved acoustic pressure and particle velocity; and a method of separating particles from a fluid comprising use of same.

IPC Classes  ?

• B01D 21/28 - Mechanical auxiliary equipment for acceleration of sedimentation, e.g. by vibrators or the like
• B01D 43/00 - Separating particles from liquids, or liquids from solids, otherwise than by sedimentation or filtration
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• G10K 15/00 - Acoustics not otherwise provided for

Abstract

1 are as defined herein are inhibitors of class I histone deacetylases and are of use in the treatment of lysosomal storage disorders, especially Niemann-Pick type C disease, as well as other lysosomal storage disorders, defective autophagy, accumulation of free cholesterol and mycobacterial diseases.

IPC Classes  ?

• C07F 9/26 - Amides of acids of phosphorus containing P-halide groups
• C07F 9/12 - Esters of phosphoric acids with hydroxyaryl compounds
• C07F 9/24 - Esteramides
• C07F 9/572 - Five-membered rings

Abstract

Microwave resonance cavities and associated methods and apparatus are described. In one example, a cavity (100) comprises a first and a second input port (102, 104) for inputting microwave radiation at a first and a second frequency respectively. The microwave radiation at the first frequency may be to excite a sample in the cavity whereas the microwave radiation at the second frequency may be to interrogate a sample in the cavity for analysis. The cavity has dimensions such that it resonates at both the first and the second frequency.

IPC Classes  ?

• G01R 33/60 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance
• G01N 22/00 - Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more
• G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
• G01R 33/345 - Constructional details, e.g. resonators of waveguide type
• H01P 7/06 - Cavity resonators

Abstract

Methods and apparatus for analysis of nano-objects using wide-field bright field transmission techniques are described. Such methods may comprise acquiring a plurality of images of a sample comprising a plurality of nano-objects using bright field illumination via a continuously variable spectral filter, and identifying a nano-object within the sample in the plurality of images, wherein the position of the nano-object changes between images. Using data extracted from the plurality of images, an extinction cross-section of the identified nano-object may be quantitatively determined.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials

Abstract

An SOP for connection to a first feeder in an electricity distribution network, the SOP being configured to, when a feeder connected to the SOP is faulty, apply a diagnostic voltage to the feeder and make current and voltage measurements at the connection of the SOP to the feeder while the diagnostic voltage is being applied.

IPC Classes  ?

• G01R 31/42 - AC power supplies
• H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks
• H02J 13/00 - Circuit arrangements for providing remote indication of network conditions, e.g. an instantaneous record of the open or closed condition of each circuitbreaker in the networkCircuit arrangements for providing remote control of switching means in a power distribution network, e.g. switching in and out of current consumers by using a pulse code signal carried by the network
• H02M 1/32 - Means for protecting converters other than by automatic disconnection
• H02J 3/36 - Arrangements for transfer of electric power between ac networks via a high-tension dc link

Abstract

Compounds that can be used as catalysts, particularly compounds that can be used as catalysts in ring-opening polymerization reactions and/or isocyanate trimerization reactions.

IPC Classes  ?

• C07D 213/53 - Nitrogen atoms

Abstract

A method of direct oxidation of a hydrocarbon to produce an oxygenated reaction product, wherein said method comprises contacting a peroxide and oxygen and the hydrocarbon with a suspension of catalyst particles dispersed in a liquid reaction medium, wherein the catalyst particles are unsupported and comprise at least one transition metal.

IPC Classes  ?

• C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
• B01J 23/52 - Gold
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 35/02 - Solids
• B01J 37/16 - Reducing

Abstract

A catalyst comprising atomically dispersed cationic gold or ruthenium or palladium or platinum species and method of making thereof.

IPC Classes  ?

• C07C 17/08 - Preparation of halogenated hydrocarbons by addition of hydrogen halides to unsaturated hydrocarbons
• B01J 23/42 - Platinum
• B01J 23/44 - Palladium
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 23/52 - Gold
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B01J 31/30 - Halides
• B01J 27/10 - Chlorides
• B01J 27/13 - Platinum group metals

Abstract

The invention relates to a compound of General Formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein. Compounds and compositions comprising the same exhibit high serum stability and potent activation of the ?d T-cell immune response, so are suitable for use in immunotherapy. The invention also relates to methods of immunotherapy using the compounds of General Formula (I).

IPC Classes  ?

• A61K 31/664 - Amides of phosphorus acids
• A61P 19/00 - Drugs for skeletal disorders
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07F 9/44 - Amides thereof

Abstract

The invention relates to a compound of General Formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein. Compounds and compositions comprising the same exhibit high serum stability and potent activation of the γδ T-cell immune response, so are suitable for use in immunotherapy. The invention also relates to methods of immunotherapy using the compounds of General Formula (I).

IPC Classes  ?

• C07F 9/44 - Amides thereof
• A61P 19/00 - Drugs for skeletal disorders
• A61K 31/664 - Amides of phosphorus acids
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The present disclosure relates to an immunogenic agent comprising Dna J heat shock protein family (Hsp40) member B7 or an immunogenic fragment thereof; a DNA vaccine comprising a nucleic acid encoding said protein or at least one immunogenic fragment thereof; a pharmaceutical composition or vector or DNA vaccine for use in the treatment of cancer; and a method of treating cancer comprising the use of said immunogenic agent or pharmaceutical composition or vector or DNA vaccine.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to an immunogenic agent comprising Dna J heat shock protein family (Hsp40) member B7 or an immunogenic fragment thereof; a DNA vaccine comprising a nucleic acid encoding said protein or at least one immunogenic fragment thereof; a pharmaceutical composition or vector or DNA vaccine for use in the treatment of cancer; and a method of treating cancer comprising the use of said immunogenic agent or pharmaceutical composition or vector or DNA vaccine.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a polymer comprising a polymer chain of general formula (I): wherein R1is H or methyl; R21-61-6 alkyl R3is H or methyl; R42pp-N+322322O-2p322; p is an integer of 1 to 4; n is an integer of 15 to 30; and m is an integer wherein the ratio of n:m is from 80:20 to 20:80; provided that at least 90% of the R42PP-N+322322O- The invention also relates to nanoparticles formed from the polymers and to pharmaceutical compositions comprising an active agent encapsulated in the nanoparticles.

IPC Classes  ?

• C08F 220/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
• C08F 220/38 - Esters containing sulfur
• C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
• C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
• C08F 8/34 - Introducing sulfur atoms or sulfur-containing groups
• C08F 8/44 - Preparation of metal salts or ammonium salts
• C08F 220/34 - Esters containing nitrogen
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C08F 120/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids

Abstract

The invention concerns a mutant luciferase protein; a nucleic acid molecule encoding same and a vector comprising said nucleic acid molecule; use of said mutant luciferase protein in a bioluminescence assay, including in vivo imaging; a reporter system comprising said mutant luciferase protein and a kit including at least said mutant luciferase protein.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase

Abstract

The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterised by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Abstract

The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

ν3ν55 integrin.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention concerns a modified oncolytic adenovirus of serotype Ad5; a pharmaceutical composition comprising same; and a method of treating cancer using same wherein said modified adenovirus comprises at least one point mutation(s) in the hexon hypervariable region 7 (HVR7 mutation) to prevent vims binding with coagulation factor 10 (FX); at least one point mutation(s) in the fiber knob region AB loop (KOI mutation) to prevent vims binding with the coxsackie and adenovirus receptor (CAR); and at least one point mutation(s) in the penton integrin binding motif Arg-Gly-Asp (RGD) to prevent vims binding with Oyps/Oyps integrin.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to an artificial cell system comprising at least one droplet-interface bilayer (DIB) encased within a shell; a suspension comprising same; and a method and a device for the manufacture of same.

IPC Classes  ?

• A61K 9/107 - Emulsions
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The invention relates to inhibitors of MAPK3(ERK1 MAP kinase), in particular to polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents.The invention also concerns related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway.Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 38/45 - Transferases (2)

Abstract

The invention relates to inhibitors of MAPK3(ERK1 MAP kinase), in particular to polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents.The invention also concerns related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway.Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/725 - T-cell receptors
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

This application relates to a water treatment process. The process comprises contacting contaminated water with a catalyst, introducing hydrogen and an oxygen-containing gas into the contaminated water, and reacting hydrogen and oxygen in the presence of the catalyst and the contaminated water.

IPC Classes  ?

• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 23/44 - Palladium
• B01J 23/52 - Gold
• B01J 23/62 - Platinum group metals with gallium, indium, thallium, germanium, tin or lead
• B01J 37/08 - Heat treatment
• B01J 37/18 - Reducing with gases containing free hydrogen
• C01B 15/029 - Preparation from hydrogen and oxygen
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
• C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/725 - T-cell receptors

Abstract

The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans